Published in Health Serv Res on May 24, 2010
Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Res Social Adm Pharm (2013) 0.91
Historical trend of disparity implications of Medicare MTM eligibility criteria. Res Social Adm Pharm (2012) 0.89
Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population. J Am Pharm Assoc (2003) (2012) 0.86
Predictors of medication-related problems among medicaid patients participating in a pharmacist-provided telephonic medication therapy management program. Pharmacotherapy (2014) 0.81
Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. Am Health Drug Benefits (2014) 0.79
Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review. Expert Rev Pharmacoecon Outcomes Res (2013) 0.78
Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population. Res Social Adm Pharm (2014) 0.78
Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. J Manag Care Spec Pharm (2015) 0.77
Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. J Pharm Health Serv Res (2014) 0.77
Trends in Medicare Part D Medication Therapy Management Eligibility Criteria. Am Health Drug Benefits (2015) 0.77
Racial and ethnic disparities in influenza vaccinations among community pharmacy patients and non-community pharmacy respondents. Res Social Adm Pharm (2013) 0.75
Contingent valuation and pharmacists' acceptable levels of compensation for medication therapy management services. Res Social Adm Pharm (2012) 0.75
Disparity Implications of Proposed 2015 Medicare Eligibility Criteria for Medication Therapy Management Services. J Pharm Health Serv Res (2016) 0.75
Racial residential segregation: a fundamental cause of racial disparities in health. Public Health Rep (2002) 13.49
Levels of racism: a theoretic framework and a gardener's tale. Am J Public Health (2000) 5.49
Medication Therapy Management in community pharmacy practice: core elements of an MTM service (version 1.0). J Am Pharm Assoc (2003) (2005) 3.43
Definition of medication therapy management: development of professionwide consensus. J Am Pharm Assoc (2003) (2005) 2.62
Invited commentary: "race," racism, and the practice of epidemiology. Am J Epidemiol (2001) 2.35
Medicare program; Medicare prescription drug benefit. Final rule. Fed Regist (2005) 2.35
Dissemination of Evidence-based Practice Center reports. Ann Intern Med (2005) 2.05
The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) (2003) 2.00
Diabetes Ten City Challenge: final economic and clinical results. J Am Pharm Assoc (2003) (2009) 1.91
Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs. J Manag Care Pharm (2007) 1.86
Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ Rev (2003) 1.67
Equity versus efficiency: a dilemma for the NHS. If the NHS is serious about equity it must offer guidance when principles conflict. BMJ (2001) 1.46
Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res (2007) 1.16
Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Med Care Res Rev (2006) 1.13
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Racial disparities in prescription drug use among dually eligible beneficiaries. Health Care Financ Rev (2003) 1.02
The economic implications of the racial and ethnic disparities in the use of selective serotonin reuptake inhibitors. Curr Med Res Opin (2007) 0.95
Two-year changes in health and functional status among elderly Medicare beneficiaries in HMOs and fee-for-service. Health Serv Res (2000) 0.93
Disparities in health care: minority elders at risk. ABNF J (2007) 0.92
A comparison of direct medical costs across racial and ethnic groups among children with cancer. Curr Med Res Opin (2008) 0.88
Pharmacist-provided medication therapy management (part 2): Payer perspectives in 2007. J Am Pharm Assoc (2003) (2008) 0.87
Shifting the focus from cost to value: a government perspective. J Manag Care Pharm (2006) 0.84
Effect on health outcomes of a community-based medication therapy management program for seniors with limited incomes. Am J Health Syst Pharm (2006) 0.80
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract (2011) 4.69
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health (2007) 3.05
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Patterns and correlates of linkage to appropriate HIV care after HIV diagnosis in the US Medicaid population. Sex Transm Dis (2013) 2.92
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol (2012) 2.82
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol (2012) 2.38
Diabetes and hypertension: the bad companions. Lancet (2012) 2.10
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm (2014) 2.03
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc (2003) (2008) 1.93
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
Cost-of-illness studies : a review of current methods. Pharmacoeconomics (2006) 1.84
Patients' attitudes about living donor transplantation and living donor nephrectomy. Am J Kidney Dis (2003) 1.80
A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics (2004) 1.79
Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care (2010) 1.75
Epidemiology of type 2 diabetes: focus on ethnic minorities. Med Clin North Am (2005) 1.71
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) (2011) 1.59
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med (2010) 1.57
Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care (2012) 1.55
Pharmacists' and patients' roles in the pharmacist-patient relationship: are pharmacists and patients reading from the same relationship script? Res Social Adm Pharm (2007) 1.53
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health (2005) 1.50
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. J Am Dent Assoc (2002) 1.49
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology (2011) 1.44
Energy adaptation to glucocorticoid-induced hyperleptinemia in human beings. Metabolism (2005) 1.43
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. Am J Nephrol (2015) 1.42
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract (2011) 1.41
Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. J Manag Care Pharm (2004) 1.40
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. Am J Manag Care (2011) 1.39
Hypertension and heart failure. Roundtable discussion. J Clin Hypertens (Greenwich) (2004) 1.38
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J (2007) 1.33
Sociological influences on antidepressant prescribing. Soc Sci Med (2003) 1.24
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med (2005) 1.24
Center effects in anemia management of dialysis patients. J Am Soc Nephrol (2007) 1.22
Exploring donors' and recipients' attitudes about living donor kidney transplantation. Prog Transplant (2003) 1.22
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res (2007) 1.16
Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol (2008) 1.14
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med (2002) 1.13
Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Med Care Res Rev (2006) 1.13
Barriers to self-management of diabetes: a qualitative study among low-income minority diabetics. Ethn Dis (2011) 1.12
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc (2009) 1.11
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clin Trials (2013) 1.11
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant (2007) 1.10
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab (2013) 1.08
Hemoglobin A1c diagnostic cutoff differences between black and white persons. Ann Intern Med (2013) 1.07
The development of direct-to-consumer prescription drug advertising regulation. Food Drug Law J (2002) 1.06
Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals. Arch Intern Med (2003) 1.06
Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. Am J Manag Care (2004) 1.06
Value of community pharmacy residency programs: college of pharmacy and practice site perspectives. J Am Pharm Assoc (2003) (2010) 1.05
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol (2012) 1.03
Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care (2009) 1.02
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) (2005) 1.02
Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab (2008) 1.01
Provision of risk management and risk assessment information: the role of the pharmacist. Res Social Adm Pharm (2006) 1.01
Prediabetes as a therapeutic target. Clin Chem (2010) 1.01
Work profiles identified from the 2007 Pharmacist and Pharmaceutical Scientist Career Pathway Profile Survey. Am J Pharm Educ (2008) 1.01
Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech? Expert Rev Pharmacoecon Outcomes Res (2014) 1.01
Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst (2013) 1.00
Medication access through patient assistance programs. Am J Health Syst Pharm (2006) 1.00
Reasons for discharges against medical advice: a qualitative study. Qual Saf Health Care (2010) 0.99
Drug therapy persistence and stroke recurrence. Am J Manag Care (2006) 0.98
The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care (2009) 0.98
Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer (2011) 0.97